58,396 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Purchased by Edgestream Partners L.P.

Edgestream Partners L.P. purchased a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 58,396 shares of the biopharmaceutical company's stock, valued at approximately $477,000.

Several other large investors have also recently added to or reduced their stakes in FOLD. Vanguard Group Inc. increased its holdings in Amicus Therapeutics by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 29,258,963 shares of the biopharmaceutical company's stock valued at $275,619,000 after buying an additional 458,143 shares in the last quarter. Wellington Management Group LLP increased its holdings in Amicus Therapeutics by 18.8% in the fourth quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company's stock valued at $268,112,000 after buying an additional 4,497,950 shares in the last quarter. Nuveen Asset Management LLC increased its holdings in Amicus Therapeutics by 4.4% in the fourth quarter. Nuveen Asset Management LLC now owns 3,807,420 shares of the biopharmaceutical company's stock valued at $35,866,000 after buying an additional 159,139 shares in the last quarter. Northern Trust Corp increased its holdings in Amicus Therapeutics by 5.9% in the fourth quarter. Northern Trust Corp now owns 3,371,639 shares of the biopharmaceutical company's stock valued at $31,761,000 after buying an additional 187,652 shares in the last quarter. Finally, Vestal Point Capital LP purchased a new position in Amicus Therapeutics in the fourth quarter valued at about $31,557,000.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on FOLD. The Goldman Sachs Group dropped their price objective on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. UBS Group raised their price objective on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Wall Street Zen cut shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Finally, Morgan Stanley raised shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research note on Thursday. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $16.22.

Amicus Therapeutics Stock Down 5.2%

Shares of NASDAQ FOLD opened at $5.96 on Friday. Amicus Therapeutics, Inc. has a 1 year low of $5.51 and a 1 year high of $12.65. The firm's 50 day moving average price is $6.07 and its 200 day moving average price is $7.65. The firm has a market cap of $1.84 billion, a P/E ratio of -66.21 and a beta of 0.51. The company has a debt-to-equity ratio of 2.02, a quick ratio of 2.47 and a current ratio of 3.34.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.